BIOPROCESSING MARKET TRENDS AND OUTSOURCING DYNAMICS: 2016-2021A P R I L , 2 0 1 6

P R E V I E W O F

REPORT OVERVIEW

HOW YOU CAN USE THIS REPORT

D A T A C O L L E C T I O N I N Q 1 , 2 0 1 6

3 0 - M I N U T E W E B - B A S E D

S U R V E Y

79 PAGES

75 CHARTS

AND GRAPHS

VALUABLE FOR

MAJOR SECTIONS:1. Bioprocessing Market

Dynamics

2. Service Provider Perceptions and Selection

3. Trends, Predictions and Preferences

4. Study Data

Introduction

SMARTER QUESTIONS SMARTER ANSWERS

Full table of contents included on next page.

DRUG DEVELOPERS• Gain insight into where the biologics industry is heading over

the next five years with respect to protein expression systems utilized and types of biologics in development

• Understand the CMO usage patterns of industry peers to identify whether additional outsourcing advatanges can be obtained for your organization

• Learn the criteria used by peers to select bioprocessing contract manufacturers that help to scientifically and strategically evaluate service providers for bioprocessing projects

CONTRACT MANUFACTURERS• Pinpoint which CMO attributes have led to successful

outsourcing relationships, those that have caused service providers to lose bids and what truly drives sponsor satisfaction, then internally assess your company on these metrics

• Identify changes in demand for outsourced activities and services in order to prepare for future needs

• Better position your company to win business by understanding the dynamics of different buyer groups (by sponsor company type and geography) and developing targeted marketing to speak directly to their unique needs

PHARMA/BIOTECH

OUTSOURCING

CMO MARKETING

BUSINESS DEVELOPMENT

EXECUTIVE MANAGEMENT

OPERATIONS

Manufacturing biologics is a much more involved and

complicated process than the chemical synthesis required

for small molecule drugs. As a result, some sponsors are

unlikely to outsource the process because of its complexity.

Others are more likely to outsource bioprocessing because

they need access to scientific expertise not possessed in-

house.

ISR’s Bioprocessing Market Trends and Outsourcing

Dynamics: 2016-2021 report affords readers the opportunity

to gain insight into the bioprocessing market and where it’s

heading. This report provides an overview of the current

market dynamics for bioprocessing as well as an outlook

on what our survey respondents predict the marketplace

will look like in five years. The report also explores the

types of biologics sponsor organizations currently have

in development and on the market and the likelihood of

outsourcing a bioprocessing project by the type of biologic.

1 0 0 R E S P O N D E N T S F R O M N O R T H

A M E R I C A , E U R O P E , A N D A S I A

Introduction

SMARTER QUESTIONS SMARTER ANSWERS

STUDY FINDINGS

10www.ISRreports.com ©2016 Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021

Bioprocessing Project & CMO VolumeThe average number of bioprocessing projects per year skews high at 14�4 due to the substantial proportion of respondents from large biopharma companies, where an average of 20�4 bioprocessing projects per year are conducted� More than half of all bioprocessing projects are outsourced, and an average of 5�7 contract manufacturers are engaged to fulfill sponsor companies’ bioprocessing needs�

Large biopharma companies use an average of 7�1 CMOs, more than twice as many as non-large companies require to meet their outsourced bioprocessing needs (3�1)� Non-large biopharma outsources a much higher proportion of their bioprocessing than large biopharma (74% vs 48%), which relates back to non-large biopharmaceutical companies using CMOs for all of their manufacturing needs�

Respondents who work for biopharmaceutical companies headquartered in Europe averaged more bioprocessing projects per year than their North American counterparts� While outsourcing rates are similar (54% Europe vs 58% North America), European biopharmas require fewer CMOs on average (4�2 vs 6�5)�

“About how many bioprocessing projects (both in-house and outsourced) would you estimate your company conducts on average per year?” (Base=100)

“Overall, what proportion of your organization’s bioprocessing is currently outsourced? Your best estimate is fine. Responses must be between 0% and 100%.” (Base=100)

“How many CMOs does your company work with to meet its bioprocessing needs?” (Base=100)        

4.2

6.5

3.1

7.1

5.7

54%

58%

74%

48%

57%

18.2

13.0

3.3

20.4

14.4

0 10 20 30 40 50 60 70 80

Western Europe (n=31)

North America (n=67)

Non-large Biopharma - R&D <$1B (N=36)

Large Biopharma - R&D $1B+ (n=64)

Overall (n=100)

# of Projects / % Outsourced / # of CMOs

Average # of Projects

% Outsourced

Average # of CMOs

© Industry Standard Research

S A M P L E P A G E :

BIOPROCESSING PROJECT & CMO VOLUMEISR surveyed 100 respondents at pharma and biotech companies. The Bioprocessing Market Dynamics section of this report includes data regarding current outsourcing volume, types of biologics outsourced, and predictions for future trends in the market.

This page details the average number of bioprocessing projects at each company, the percentage of these projects that are outsourced, and the average number of CMOs each company works with on bioprocessing projects.

Full data is available in the report.

C L O S E R L O O K

Understanding project volume and the degree to which bioprocessing is outsourced helps both drug developers and CMOs make strategic decisions.

Learn more in the full report:

www.ISRreports.com

STUDY FINDINGS

10www.ISRreports.com ©2016 Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021

Bioprocessing Project & CMO VolumeThe average number of bioprocessing projects per year skews high at 14�4 due to the substantial proportion of respondents from large biopharma companies, where an average of 20�4 bioprocessing projects per year are conducted� More than half of all bioprocessing projects are outsourced, and an average of 5�7 contract manufacturers are engaged to fulfill sponsor companies’ bioprocessing needs�

Large biopharma companies use an average of 7�1 CMOs, more than twice as many as non-large companies require to meet their outsourced bioprocessing needs (3�1)� Non-large biopharma outsources a much higher proportion of their bioprocessing than large biopharma (74% vs 48%), which relates back to non-large biopharmaceutical companies using CMOs for all of their manufacturing needs�

Respondents who work for biopharmaceutical companies headquartered in Europe averaged more bioprocessing projects per year than their North American counterparts� While outsourcing rates are similar (54% Europe vs 58% North America), European biopharmas require fewer CMOs on average (4�2 vs 6�5)�

“About how many bioprocessing projects (both in-house and outsourced) would you estimate your company conducts on average per year?” (Base=100)

“Overall, what proportion of your organization’s bioprocessing is currently outsourced? Your best estimate is fine. Responses must be between 0% and 100%.” (Base=100)

“How many CMOs does your company work with to meet its bioprocessing needs?” (Base=100)        

4.2

6.5

3.1

7.1

5.7

54%

58%

74%

48%

57%

18.2

13.0

3.3

20.4

14.4

0 10 20 30 40 50 60 70 80

Western Europe (n=31)

North America (n=67)

Non-large Biopharma - R&D <$1B (N=36)

Large Biopharma - R&D $1B+ (n=64)

Overall (n=100)

# of Projects / % Outsourced / # of CMOs

Average # of Projects

% Outsourced

Average # of CMOs

© Industry Standard Research

The average number of bioprocessing projects per year skews high at 14.4 due to the substantial proportion of respondents from large biopharma companies, where an average of 20.4 bioprocessing projects per year are conducted. More than half of all bioprocessing projects are outsourced, and an average of 5.7 contract manufacturers are engaged to fulfill sponsor companies’ bioprocessing needs.

“About how many bioprocessing projects (both in-house and outsourced) would you estimate your company conducts on average per year?” (Base=100)

“Overall, what proportion of your organization’s bioprocessing is currently outsourced? Your best estimate is fine. Responses must be between 0% and 100%.” (Base=100)

“How many CMOs does your company work with to meet its bioprocessing needs?” (Base=100)

D A T A I N F U L L R E P O R T

D A T A I N F U L L R E P O R T

Introduction

SMARTER QUESTIONS SMARTER ANSWERS

Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.   For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.

ABOUT INDUSTRY STANDARD RESEARCH

>> R E G I S T E R N O W>>Receive $250 instant credit towards any ISR report

>>Earn 10% credit towards all future purchases

>>Receive advanced notifications on ISR’s latest reports and free resources

SAVE ON THIS, OR ANY ISR REPORT, BY CREATING A FREE ACCOUNT

MORE INFORMATION

To get more information about this report, including the full table of contents, sample pages, and pricing, please download the full preview from ISR’s website:

https://www.isrreports.com/reports/bioprocessing-market-trends-and-outsourcing-dynamics-2016-2021/

TO LEARN MORE: CONTACT US AT INFO@ISRREPORTS.COM OR +1(919)301-0106

Biosimilars & Biologics

Clinical Trial Recruitment &

Retention

Commercialization Department Models & Structures

Trends & Technologies

Manufacturing Service Provider Quality Benchmarking

CUSTOM RESEARCH

UNDERSTAND YOUR MARKETSLeverage ISR’s experience and institutional knowledge to create a fit-for-purpose market research project that addresses the business decisions you need to make.

Are you:• Developing a new product or service?• Evaluating a new market?• Targeting a new customer segment?• Entering a new geography?• Needing a deeper understanding of your

customer or potential customer base?

UNDERSTAND YOUR CUSTOMERSWho makes the decisions and in what contexts? ISR can help you gain a deeper understanding of your customers’ decision-making units (DMUs) and decision-making processes (DMPs).

Key Questions Addressed:• What motivates the purchase decision?• How are companies, products, solutions, and/or

brands evaluated?• What factors drive the final buying decision?• Where are your customers won or lost in the

purchasing process?• Why were specific opportunities won or lost?• How do you keep customers engaged and

manage their loyalty over time?

CUSTOM RESEARCH SERVICES• Investigator Forum• Brand, Advertising, and Message Testing• Loyalty Management• New Product and Service Development• Competitive Intelligence• Strategy War Games• MORE

S O M E T H I N G T O C O N S I D E R

DISTINCTIVE – Receive novel insights from industry decision-makers on topics including: service provider quality, patient recruitment, biosimilars, clinical technology, manufacturing, clinical operations, and commercial activities.

UNRESTRICTED – ISR doesn’t sell seats. Instantly obtain access for all employees within your organization

AFFORDABLE – Receive access to ALL reports in ISR’s library, as well as those released during your subscription period. ISR’s competitive library pricing equates to the cost of a few individual report purchases.

LIBRARY ACCESS SUBSCRIPTIONISR’s library access subscription provides your entire organization access to our full library of syndicated market research reports (100+ titles) plus access to all reports (~25 per year) released during your subscription period. Our research categories include:

THE ISR DIFFERENCE

Mostly primary research; always appropriate for the topic

One size fits all; usually publically available data

To learn more, visit www.ISRreports.com

ISR’S REPORTS

THECOMMON

SYNDICATEDREPORT

VS.

RESEARCH METHODS

ISR’s proprietary data tools and channelssupport fast, high quality data collection

Struggle to recurit the right targets and enough of them

DATA COLLECTION

Sophisticated screening ensures genuine decision-makers make up respondents

Undisclosed methodologies and respondent demographics

RESPONDENTS

Robust sample sizes that instill confidence

Often insu­cient industry representationthat leaves you defending results

SAMPLE SIZE

Decades of experience means more insights that are immediately usable

Junior analysts capable of reporting numbers

ANALYSTS

ISR’S HEALTH PANELThe industry’s fastest growing panel of health care and pharmaceutical

professionals, with nearly 1,500 members worldwide.

BYJOB

LEVEL

Director 46%

Manager 29%

C-level 13%

VP 10%

BYEXPERIENCE

IN YEARS

16-20 years 23%

11-15 years 24%

6-10 years 11%

3-5 years 5%

20+ years 37%

BYCOMPANY

TYPE

Other 6%

Sponsor 78%

CRO 6%

ResearchSite 10%